Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
26 11월 2024 - 8:00PM
Business Wire
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced that management
will present at the Piper Sandler 36th Annual Healthcare Conference
on Tuesday, December 3, 2024, at 1 pm ET.
The presentation will be webcast live; a link for the webcast
can be found on the Edgewise Events & Presentations page and
will be accessible for replay, for a limited time, following the
conference. It is recommended that users connect to the live
webcast several minutes prior to the start to ensure a timely
connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of
novel therapeutics. Sevasemten is an orally administered
first-in-class fast skeletal myosin inhibitor in late-stage
clinical trials in Becker and Duchenne muscular dystrophies.
EDG-7500 is a novel cardiac sarcomere modulator for the treatment
of hypertrophic cardiomyopathy and other diseases of diastolic
dysfunction, currently in Phase 2 clinical development. The entire
team at Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X ,
Facebook and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241126273809/en/
Edgewise Contacts Investors: Michael Carruthers,
Chief Financial Officer ir@edgewisetx.com
Media: Maureen Franco, VP Corporate Communications
media@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Edgewise Therapeutics (NASDAQ:EWTX)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
